Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial

BACKGROUND: Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and hepatocellular carcinoma. Treatment with first generation protease inhibitors (PI) + peg-interferon (pegIFN) and ribavirin (RBV) achieved sustained virologic response (SVR) rates of 65–75% but was associate...

Descripción completa

Detalles Bibliográficos
Autores principales: Deutsch, Liat, Houri, Inbal, Ben-Ari, Ziv, Shlomai, Amir, Veitsman, Ella, Cohen-Ezra, Oranit, Issachar, Assaf, Mor, Orna, Gozlan, Yael, Bruck, Rafael, Menachem, Yoram, Zelber-Sagi, Shira, Katchman, Helena, Shibolet, Oren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126165/
https://www.ncbi.nlm.nih.gov/pubmed/32245397
http://dx.doi.org/10.1186/s12879-020-4921-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126165/
https://www.ncbi.nlm.nih.gov/pubmed/32245397
http://dx.doi.org/10.1186/s12879-020-4921-3

Ejemplares similares